Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.
Edward ArmstrongMatthew K L ChiuShane FooLizzie AppletonPablo NenclaresAnton PatrikeevNitya MohanMartin MclaughlinGalabina BozhanovaJulia HoebartVictoria RoulstoneEmmanuel C PatinMalin PedersenJoan KyulaMasahiro OnoFiona Errington-MaisJohn Cameron BellKevin J HarringtonAlan A MelcherVictoria JenningsPublished in: Journal for immunotherapy of cancer (2024)
Addition of αPD-1 to MG1 is required to overcome viral therapy resistance in immunologically 'colder' more advanced melanoma, highlighting the importance of tumor burden to different types of immunotherapy.